杭州安旭生物科技股份有限公司2025年度业绩快报公告

Financial Performance Summary - In 2025, the company achieved operating revenue of 453.58 million yuan, a decrease of 16.11% compared to the previous year [2] - The net profit attributable to the parent company was 73.38 million yuan, down 61.84% year-on-year [2] - The net profit attributable to the parent company after deducting non-recurring gains and losses was 15.37 million yuan, a decline of 59.44% from the previous year [2] - Total assets at the end of the reporting period were 5.61 billion yuan, a decrease of 2.72% from the end of the previous year [2] - Equity attributable to the parent company was 5.17 billion yuan, down 0.64% from the previous year [2] Operational and Strategic Developments - The company focused on stable development of its main business, integrating existing high-quality technology resources, and increasing strategic investment in new technology platforms [2] - The company made significant progress in domestic and international product registration and certification, reinforcing its long-term competitive advantage in the industry [2] - The company implemented lean management to enhance operational efficiency and cost control, resulting in notable improvements in quality and efficiency [2] - The company expanded its overseas branch layout, achieving positive progress in international market development, which increased sales expenses but opened up future growth opportunities [2] Factors Affecting Financial Results - The decline in net profit was attributed to multiple external factors, including increased tariffs imposed by the U.S. government, which led to reduced orders in certain regional markets and increased operating costs [3] - Other contributing factors included exchange rate fluctuations resulting in foreign exchange losses, decreased interest income, and asset depreciation [3] - Significant declines in operating profit, total profit, and basic earnings per share were noted, with decreases of 66.73%, 64.34%, and 61.59% respectively, primarily due to the impact of tariffs and increased expenses from overseas market expansion [4]